Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H34N5O10.Gd |
Molecular Weight | 661.76 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O
InChI
InChIKey=HBEAOBRDTOXWRZ-UHFFFAOYSA-K
InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7960618http://www.prnewswire.com/news-releases/fda-approves-dotarem-gadoterate-meglumine-first-macrocyclic-and-ionic-gadolinium-based-contrast-agent-in-usa-199354771.html
Curator's Comment: # Schering AG (now subsidiary of Bayer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/31179770 |
105.0 mM [Ki] | ||
Target ID: P52209 Gene ID: 5226.0 Gene Symbol: PGD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20235752 |
73.0 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DOTAREM Approved UseIndicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Launch Date2013 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date2011 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date2011 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date2011 |
PubMed
Title | Date | PubMed |
---|---|---|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Gadolinium-containing contrast media for radiographic examinations: a position paper. | 2002 Oct |
|
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. | 2005 Apr 20 |
|
Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data. | 2007 Aug |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
OPTIMARK (AUTHORIZED: MAGNETIC RESONANCE IMAGING)
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
||
|
WHO-VATC |
QV08CA06
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
||
|
WHO-ATC |
V08CA06
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
||
|
NCI_THESAURUS |
C62358
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
||
|
NDF-RT |
N0000175862
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
||
|
NDF-RT |
N0000180184
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
131069-91-5
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
7261
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
1287675
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
31644
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200457
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
RLM74T3Z9D
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
228833
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
C112666
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
m5629
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
FF-40
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
DB00538
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
Gadoversetamide
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
7550
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
444013
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
4147
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
SUB07867MIG
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
100000091667
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
C47545
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY | |||
|
GADOVERSETAMIDE
Created by
admin on Fri Dec 15 15:55:10 GMT 2023 , Edited by admin on Fri Dec 15 15:55:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD